Get startedLog in
    Picture of Lexicon Pharmaceuticals logo

    LXRX — Lexicon Pharmaceuticals News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMid CapMomentum Trap
    All News

    Lexicon to license obesity drug to Novo Nordisk in up to $1 billion deal

    Picture of Lexicon Pharmaceuticals logoLexicon Pharmaceuticals
    28/03/2025 11:39
    March 28 (Reuters) - Lexicon Pharmaceuticals LXRX.O said on Friday it has entered into an agreement with Novo Nordisk NOVOb.CO to license its  non-incretin-based experimental obesity drug for up to $1 billion.

 (Reporting by Sneha S K; Editing by Krishna Chandra Eluri)

 ((Sneha.SK@thomsonreuters.com;))

    Recent news on Lexicon Pharmaceuticals

    See all news